Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17621579 | 0.82 | ALDH1A1 (0.32) | ALDH1A1POLBKMT2AFDPSCYP2E1 | |
| SCHEMBL17616430 | 0.78 | TLR7 (0.32) | — | |
| SCHEMBL2930973 | 0.76 | ALDH1A1 (0.38) | ALDH1A1POLBKMT2ATSHRFDPS | |
| SCHEMBL17545157 | 0.75 | KMT2A (0.32) | POLBKMT2A | |
| SCHEMBL19622429 | 0.72 | KMT2A (0.35) | ALDH1A1POLBKMT2ATSHRFDPS | |
| SCHEMBL28036586 | 0.70 | ALDH1A1 (0.36) | ALDH1A1POLBKMT2ATSHRFDPS | |
| SCHEMBL14459642 | 0.69 | ALDH1A1 (0.41) | ALDH1A1POLBKMT2ATSHRFDPS | |
| SCHEMBL17616423 | 0.69 | ALDH1A1 (0.33) | ALDH1A1POLBKMT2AFDPSCYP2E1 | |
| SCHEMBL23867596 | 0.68 | SMN1; SMN2 (0.38) | ALDH1A1KMT2ATSHRFDPS | |
| Ammonia Solution, Strong SCHEMBL29243780 | 0.68 | ALDH1A1 (0.35) | ALDH1A1POLBKMT2ATSHRFDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11976072-B2 | Diacylglycerol kinase modulating compounds | GILEAD SCIENCES, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| EP-4359415-A1 | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2024-05-01 | — | — | EP | disclosed |
| CN-117355531-A | Diacylglycerol kinase modulating compounds | 吉利德科学公司 | 2024-01-05 | — | — | CN | disclosed |
| US-20230060354-A1 | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-03-02 | — | — | US | disclosed |
| WO-2022271684-A1 | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022271684-A1 | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| EP-3186239-B1 | ANTIRETROVIRAL AGENTS | GILEAD SCIENCES INC (US) | 2018-10-10 | — | — | EP | disclosed |
| US-9873680-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873680-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873680-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| EP-3186239-A1 | ANTIRETROVIRAL AGENTS | Gilead Sciences, Inc. (US) | 2017-07-05 | — | — | EP | disclosed |
| WO-2016033243-A9 | ANTIRETROVIRAL AGENTS | GILEAD SCIENCES, INC. (US) | 2016-05-19 | — | — | WO | disclosed |
| WO-2016033243-A9 | ANTIRETROVIRAL AGENTS | GILEAD SCIENCES, INC. (US) | 2016-05-19 | — | — | WO | disclosed |
| US-20160083368-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-03-24 | — | — | US | disclosed |
| US-20160083368-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-03-24 | — | — | US | disclosed |
| US-20160083368-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-03-24 | — | — | US | disclosed |
| WO-2016033243-A1 | ANTIRETROVIRAL AGENTS | GILEAD SCIENCES, INC. (US) | 2016-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083368-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, G6PD | ALDH1A1 372/4885POLB 905/4885KMT2A 4702/4885 |
| US-20230060354-A1 | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | ALDH1A1 3992/4885POLB 3212/4885KMT2A 2327/4885 |
| US-11976072-B2 | Diacylglycerol kinase modulating compounds | DGKG, DGKB, DGKK | ALDH1A1 4095/4885POLB 3027/4885KMT2A 2566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.